DGAT1: A Potential Drug Target for Various Diseases (G8694)

Target Name: DGAT1

NCBI ID: G8694

DGAT1

DGAT1: A Potential Drug Target for Various Diseases

DGAT1 (acyl coenzyme A:cholesterol acyltransferase related gene 1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cardiovascular disease and metabolic disorders.

The DGAT1 gene is a member of the superfamily of 3-尾-hydroxyacyl-CoA synthase (HAS) genes, which are involved in the production of fatty acids, including cholesterol and fatty acids. HAS genes are known to play a crucial role in the The development and maintenance of cellular lipid homeostasis, and are implicated in various diseases, including cardiovascular disease, metabolic disorders, and neurodegenerative diseases.

DGAT1 is expressed in various tissues and cells, including heart muscle, liver, and fat cells. It has been shown to be involved in the production of fatty acids, including cholesterol and fatty acids, which are crucial for maintaining cellular membrane structure and function.

In addition to its role in fatty acid synthesis, DGAT1 has also been shown to play a role in cellular signaling. It is a potent negative regulator of the transcription factorNrf2, which is involved in the detoxification of environmental toxins and other harmful substances. Nrf2 is a well-known gene that has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and aging.

DGAT1 has also been shown to be involved in the regulation of cellular stress responses. It has been shown to play a role in the stress response pathway, which is involved in the regulation of cellular stress responses to environmental stimuli, such as stress, exercise, and diet.

Given its involvement in cellular signaling and its potential as a drug target, DGAT1 is an attractive candidate for further study as a potential drug or biomarker for the treatment of various diseases.

Protein Name: Diacylglycerol O-acyltransferase 1

Functions: Catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates (PubMed:16214399, PubMed:18768481, PubMed:28420705, PubMed:9756920, PubMed:32433611, PubMed:32433610). Highly expressed in epithelial cells of the small intestine and its activity is essential for the absorption of dietary fats (PubMed:18768481). In liver, plays a role in esterifying exogenous fatty acids to glycerol, and is required to synthesize fat for storage (PubMed:16214399). Also present in female mammary glands, where it produces fat in the milk (By similarity). May be involved in VLDL (very low density lipoprotein) assembly (PubMed:18768481). In contrast to DGAT2 it is not essential for survival (By similarity). Functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders (PubMed:16214399). Exhibits additional acyltransferase activities, includin acyl CoA:monoacylglycerol acyltransferase (MGAT), wax monoester and wax diester synthases (By similarity). Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705)

The "DGAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DGAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets